Host cell DNA can persist during production and processing of biotherapeutics, and must be removed and monitored to minimize risk of introducing unwanted genetic material into patients. Regulatory agencies require host cell DNA levels of drug substances to be no greater than 10-100 pg/dose, depending on the dosing regimen and cell line used for production. USP General Chapter <509> “Residual DNA Testing” recommends use of probe-based DNA quantification as a validated method for testing recombinant therapeutic products produced in either Escherichia coli (E. coli) or Chinese hamster ovary (CHO) cell lines, ensuring better sensitivity and accuracy.
Cygnus Technologies’ new AccuRes™ Host Cell DNA quantification kits offer a state-of-the-art solution to precisely and accurately quantify host cell DNA remaining during process development or in final drug substances. This all-in-one kit combines our proprietary extraction procedure with a probe-based master mix containing high-quality reagents that can recover, amplify, and quantify femtogram levels of host cell DNA. AccuRes™ Host Cell DNA Quantification Kits are offered in well or tube-based extraction formats, and are compatible with a variety of qPCR instruments, offering flexibility and cost savings without compromising sensitivity.
AccuRes™ Quantification Kit Benefits: